Article

Osteoporotic fractures associated with increased mortality risk

There is increased mortality risk associated with all major osteoporotic fractures in patients of all ages and even with minor fractures in older patients for 5 to 10 years after the fracture. A subsequent fracture results in an increased risk for an additional period.

There is increased mortality risk associated with all major osteoporotic fractures in patients of all ages and even with minor fractures in older patients for 5 to 10 years after the fracture. A subsequent fracture results in an increased risk for an additional period.

Bliuc and associates examined long-term mortality risk in 614 men and women 60 years and older from the Dubbo Osteoporosis Epidemiology Study who sustained at least 1 low-trauma fracture. Age- and sex-specific standardized mortality ratios for hip, vertebral, major, and minor fractures were compared with the overall Dubbo population.

For all participants, mortality rates increased with age. The death toll was greatest among persons with hip fracture, followed by a vertebra, major bone (eg, pelvis, proximal tibia, proximal humerus), and minor bone. Men were more likely to die of initial and subsequent fractures than women. Those who sustained any fracture or a hip fracture were at heightened risk for death for 5 years or 10 years afterward, respectively. Subsequent fracture increased the risk for another 5 years.

The authors noted that this is the first finding of increased mortality associated with minor fractures and that more attention should be paid to low-trauma fractures.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.